Lobbyist information

Amount

John F.X. Heffernan	$208,000.00
Employed Terminated 01/01/2024

Total salaries paid:      $208,000.00

Client information

Amount

Acadia Pharmaceuticals Inc.

$60,000.00

Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2024 Park Street Strategies will provide (i) strategic planning, policy advice, legislative and regulatory support services in Massachusetts; (ii) meet with advocacy organizations to develop broader support; and (iii) general consulting Services and such similar other Services from time to time throughout the term of this Agreement, as requested by ACADIA and as mutually agreed upon by the parties in writing (email is acceptable).

Acuity Strategic Partners LLC	$110,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 03/01/2024 Issues related to traumatic brain injury, education and prevention.

Amgen Inc.	$72,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 02/01/2024 Legislation, regulations, and issues related to biopharmaceuticals, health care, drug pricing, transparency, business, and taxation.

Biotechnology Innovation Organization (BIO)	$54,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2024 All Legislation and Executive Branch activities in the Commonwealth including, but not limited to, agriculture, health care, economic development, Medicaid, and other issues pertaining to biotechnology.

Karuna Pharmaceuticals, Inc.	$66,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2024 Issues related to mental health, prior authorization and Medicaid.

Massachusetts Biotechnology Council, Inc.

$120,000.00

Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2024 Any and all legislation and regulations pertaining to the healthcare system; Any issue that impacts a biopharmaceutical company's ability to market or sell its products in all sectors and markets in the Commonwealth; any policy or proposal that seeks to limit or restrict unfettered patient access to innovative medicines and therapies in the Commonwealth; implementation of Chapter 224 the Acts of 2012, health care reform, drug innovation, pharmaceuticals, recycling and disposal policies, provider and industry practices related to pharmaceuticals, drug pricing, drug transparency, prescribing, dispensing and monitoring controlled substances and related policies, patient access and prescribing related policies, Massachusetts Life Sciences Center, research and development, taxation policies, drug safety, recycling and disposal policies green bio policies. Any and all legislation, regulation, policy matters before the legislature or executive branch including the Executive Offices of the Governor and Lieutenant Governor, Executive Office of Health & Human Services, Department of Public Health, Division of Insurance, MassHealth and related matters to the Office of the Attorney General, Center for Health Information and Analysis and the Health Policy Commission.

NanoDx, Inc	$0.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 03/01/2024 Issues related to traumatic brain injury, education and prevention.

PTC Therapeutics, Inc.	$30,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2024 Relationship building with members of the Massachusetts legislature to discuss rare diseases, patient access to therapies and companies economic impact in Massachusetts.

Sage Therapeutics, Inc.	$66,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2024 Issues related to mental health, maternal mental health, telehealth, STEP therapy, prior authorization and Medicaid.

UCB, Inc.

$45,000.00

Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2024 Any issue that impacts a biopharmaceutical company's ability to market or sell its products in all sectors/markets in the Commonwealth; any laws or regulations that impose or levy taxes upon a biopharmaceutical company doing business in the Commonwealth; and, any laws or regulations which provided incentives or disincentives to biopharmaceutical companies conducting research in the Commonwealth

Total salaries received:      $623,000.00

Expenditures

Amount